D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers. Close collaborations with leading research institutes worldwide provide us with a unique opportunity to accelerate translation of cutting-edge research into revolutionary lifesaving therapeutic products for patients.
We're tracking D&D Pharmatech's market expansion
How D&D Pharmatech's international expansion compares to its competitors
D&D PharmatechYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 D&D PharmatechYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
D&D Pharmatech announced outside director Han Seol-hee resigned on May 18, 2026, for personal reasons. The outside director ratio decreased from 33.33% to 20%.
HistoIndex's AI analysis confirmed positive Phase 2 results for D&D Pharmatech's zabopegdutide in MASH treatment, showing 81.8% fibrosis improvement versus 18.8% placebo, with significant quantitative reductions in liver fibrosis.
HistoIndex and D&D Pharmatech announced positive Phase 2 trial results for zabopegdutide (DD01), a liver-targeted GLP-1/glucagon receptor agonist for MASH treatment, showing robust liver fibrosis improvement through AI-powered analysis.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about D&D Pharmatech's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
